BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that the Company will hold a live R&D webcast on Thursday, April 20th at 4 pm EDT to review its clinical development programs in Alzheimer’s disease and Parkinson’s disease.
As part of the presentation, the Company will discuss why it believes buntanetap is uniquely positioned to address both symptomatic as well as disease modification in early and advanced-stage Alzheimer’s and Parkinson’s patients. Annovis will discuss its preliminary plans to develop the drug with the FDA for all stages of the disease, short and long term, and discuss the recently announced results from the blinded, interim analysis of the ongoing Phase 3 study in Parkinson’s disease.
Participant Toll-Free Dial-In Number: 1 (888) 210-3702
Participant Toll Dial-In Number: 1 (646) 960-0191
Conference ID: 7935665
Webcast Link: https://events.q4inc.com/attendee/892955864
Following the presentation, the Company will hold a Question-and-Answer session.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.